Loading clinical trials...
Loading clinical trials...
A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Conditions
Interventions
Ruxolitinib Cream
Vehicle Cream
Locations
79
United States
Cahaba Dermatology
Birmingham, Alabama, United States
Elite Clinical Studies
Phoenix, Arizona, United States
First OC Dermatology
Fountain Valley, California, United States
Dermatology Research Associates
Los Angeles, California, United States
Dermatology Specialists Inc
Oceanside, California, United States
Integrated Research Group Inc.
Riverside, California, United States
Start Date
December 20, 2018
Primary Completion Date
December 23, 2019
Completion Date
December 1, 2020
Last Updated
September 28, 2023
NCT07262983
NCT06389136
NCT06342713
NCT07223697
NCT07290803
NCT07265479
Lead Sponsor
Incyte Corporation
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions